Skip to content

The Healthy Baby Bottoms Study

The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04101890
Enrollment
5
Registered
2019-09-24
Start date
2020-03-12
Completion date
2021-01-02
Last updated
2021-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaper Dermatitis

Brief summary

Diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. The incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the US. It is caused by skin exposure to a combination of several factors including: excessive moisture, topical irritants, reduced pH, friction, maceration and bacterial infection. When infants soil their diaper, diaper contents saturate the area raising the pH of the skin above the normal level of 5 or less, and leaving the area highly vulnerable to maceration from friction. Irritants in urine and feces are then able to penetrate the macerated skin, causing inflammation and greater skin friability. An elevation in the skin pH allows pathogenic bacteria to overgrow, and combined with the breakdown in the skin's outer epithelial barrier, can lead to bacterial infection. Theraworx Foam Formulation-Allantoin Liquid by Avadim Technologies, Inc. is a skin protectant with use for temporary protection of minor cuts, scrapes, burns and chapped or cracked skin. As such, Theraworx Foam used in the diaper area may be beneficial for protecting skin against diaper rash wounds, as well as for assisting with wound healing and reducing any associated pain. The purpose of this study is to determine caregivers' perceptions of the benefits of using Theraworx Foam on their infant's diaper area as part of their hygienic routine, including whether they feel the product is pleasant and easy to use, and whether they feel it helps prevent and reduce the severity of diaper dermatitis in their infants 1-14 months old.

Interventions

DRUGDiaper care with Theraworx

Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes

Sponsors

Avadim Technologies, Inc.
CollaboratorINDUSTRY
Linda Fu
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Read English at the 8th grade level * Have reliable access to email for 7 weeks * Complete the first online survey within 24 hours of the request * Custodial guardian of an infant between the ages of 1-12 months old living with him/her, wearing diapers, and has had ≥1 diaper rash in the 2 months preceding recruitment

Exclusion criteria

* Does not have a stable address at which to receive a package of Theraworx and is unable/unwilling to pick it up at Children's National Health System * Infant is immunocompromised, has a congenital disorder, or on the day of recruitment, has a diaper rash, has a moderate to severe illness requiring hospitalization or transfer to the emergency room, or was circumcised \<10 days prior.

Design outcomes

Primary

MeasureTime frameDescription
Caregiver's Self-report of Prevention of Diaper Dermatitis in Infant4 weeksCaregivers self-report on a weekly basis the total number of days during the past week that their infant had a diaper rash. Diaper rash was defined as the presence of one or more of the following in the diaper region: redness, skin breakdown, papules or pustules. The total number of days with diaper rash for the entire 4 week period was summed from the 4 weekly surveys (outcome measure range: 0-28 days with fewer days representing a better outcome).

Secondary

MeasureTime frameDescription
Caregiver's Self-report of Diaper Rash Severity4 weeksCaregivers used a modified Diaper Dermatitis Scale (Buckley, et al, Pediatric Dermatology 2016) to report infant diaper rash severity. The scale ranged from 0 (none) to 6 (most severe) with higher scores indicating a worse outcome. Items on the scale included assessments of rash size (0-2), redness (0-1), evidence of skin breakdown (0-1), evidence of papules (0-1) and evidence of pustules (0-1). Mean score was calculated using scores for every day over 28 days.

Countries

United States

Participant flow

Pre-assignment details

All participants completed routine diaper care during the run-in period, followed by diaper care with Theraworx during the experimental period.

Participants by arm

ArmCount
Routine Diaper Care Followed by Diaper Care With Theraworx
Participants continue their typical diaper care for 4 weeks followed immediately by 4 weeks of using Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000). During this second period, particpants apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks. Diaper care with Theraworx: Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
5
Total5

Baseline characteristics

CharacteristicRoutine Diaper Care Followed by Diaper Care With Theraworx
Age, Continuous7 months
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Frequency of diaper rash in last 30 days, continuous7 days
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 5
other
Total, other adverse events
0 / 50 / 5
serious
Total, serious adverse events
0 / 50 / 5

Outcome results

Primary

Caregiver's Self-report of Prevention of Diaper Dermatitis in Infant

Caregivers self-report on a weekly basis the total number of days during the past week that their infant had a diaper rash. Diaper rash was defined as the presence of one or more of the following in the diaper region: redness, skin breakdown, papules or pustules. The total number of days with diaper rash for the entire 4 week period was summed from the 4 weekly surveys (outcome measure range: 0-28 days with fewer days representing a better outcome).

Time frame: 4 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Routine Diaper Care Followed by Diaper Care With TheraworxCaregiver's Self-report of Prevention of Diaper Dermatitis in InfantRoutine Diaper Care3.7 daysStandard Deviation 2.5
Routine Diaper Care Followed by Diaper Care With TheraworxCaregiver's Self-report of Prevention of Diaper Dermatitis in InfantDiaper care with Theraworx1.7 daysStandard Deviation 1.5
Secondary

Caregiver's Self-report of Diaper Rash Severity

Caregivers used a modified Diaper Dermatitis Scale (Buckley, et al, Pediatric Dermatology 2016) to report infant diaper rash severity. The scale ranged from 0 (none) to 6 (most severe) with higher scores indicating a worse outcome. Items on the scale included assessments of rash size (0-2), redness (0-1), evidence of skin breakdown (0-1), evidence of papules (0-1) and evidence of pustules (0-1). Mean score was calculated using scores for every day over 28 days.

Time frame: 4 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Routine Diaper Care Followed by Diaper Care With TheraworxCaregiver's Self-report of Diaper Rash SeverityRoutine Diaper Care4.45 score on a scaleStandard Deviation 3.35
Routine Diaper Care Followed by Diaper Care With TheraworxCaregiver's Self-report of Diaper Rash SeverityDiaper Care with Theraworx3.15 score on a scaleStandard Deviation 3.82

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026